Xplico is a market leader in life science valuation. Headquartered in Denmark, we have supported 100+ companies since 2005, including top pharma/biotech companies across EU and US. We support licensing partnership, investment or fundraising decisions by providing multi-scenario valuation analysis for all parties involved, based on solid technical and market knowledge, development plans, risks and competitive environment. We suggest potential term sheets, based on benchmarked deal terms and forecasted split of revenues and costs. Xplico's unrivalled sensitivity analysis helps you to assess how any change in the development plan or market, will impact the value of the project for each party. Our clients are free to choose the level of assistance and support they need for the valuation:• A comprehensive valuation consultancy on your company/project • Tool-only: Provide you with a valuation tool (Xplico Evaluator) to build your own valuation on an advanced but flexible model• Or anything in between, tailored for your purpose Xplico Evaluator ToolXplico Evaluator is a highly specialized but flexible, easy to use valuation tool, with integrated risk assessment and powerful analysis features for the life science industry. Xplico Evaluator is built on our long experience with real needs of this industry. The tool has been fine-tuned over the years with valuable inputs from our clients and is today used by 100+ biotech and pharma companies on a day to day basis for partnering, project valuation and portfolio management.Xplico CapTable ToolXplico has recently launched an advanced cap table tool tailored to simplify complex ownership structures of life science industry. Xplico CapTable is a standardized Excel-based tool which is built and tailored to facilitate syncing up, updating and keeping accurate track of multiple ownership and exit scenarios while still easy to use.